The implications are striking. If the results hold up in larger and more definitive studies, they could open a path toward screening young children for an autoimmune predisposition to cancer — potentially years before any disease appears. Such early warning would give clinicians an unprecedented window in which to monitor, detect, and perhaps ultimately prevent tumors that today strike without warning during childhood or adolescence. For a category of cancer that has long defied prediction, the possibility of an advanced signal in the blood is a genuinely provocative prospect.

Pediatric cancers have always presented scientists with a biological puzzle. Compared with adult malignancies, cancers of childhood differ profoundly in their causes, the tissues in which they arise, their cellular origins, and their response to therapy. Children have had far less time to accumulate cancer-driving DNA damage through environmental exposures, lifestyle factors, or the slow wear of aging. As a result, pediatric tumors typically carry fewer mutations than their adult counterparts and tend to arise from less mature cells, such as stem cells or progenitor cells, whose developmental programs are still in flux. Classic models of carcinogenesis, built largely around decades of accumulated mutation, fit these diseases awkwardly at best.

The new study began with a systematic look at the proteome — the full ensemble of expressed proteins — in tumor and blood samples from 175 adults and children with sarcoma or acute lymphoblastic leukemia. The samples were collected between 2014 and 2017 through the Norwegian Sarcoma Study, the Norwegian Childhood Cancer Biobank, and the Oslo University Hospital Cancer Research Biobank. The researchers, led by corresponding author Dr. Ola Myklebost, an emeritus professor of molecular oncology at the University of Bergen, together with Serguienko and colleagues, compared these patient samples with those from healthy anonymized individuals, including blood donors and children enrolled in the Bergen Growth Study or visiting a clinic in Bergen.

What emerged from the comparison was unmistakable. Children between two and nineteen years of age with pediatric cancer carried far greater numbers of circulating IgG-class antibodies directed against DNA repair proteins than young adults or older people. These auto-antibodies concentrated their attack on a handful of key players in genome maintenance: RAD52, NUMA1, ALKBH7, APBB1, UNG, and MGMT. All of these genes are closely involved in DNA repair, yet none of them is significantly mutated in the cancers in question. In other words, the proteins themselves appeared intact — but the children’s immune systems seemed to be waging a campaign against them.

That observation raised the obvious and tantalizing question: could these auto-antibodies help explain why the children had developed cancer at all? To probe the possibility, the scientists turned to a rare and precious resource. They examined selected samples from 59 school-age children who had taken part in the United Kingdom’s Avon Longitudinal Study of Parents and Children and the Born in Bradford long-term cohort studies. Half of the children had gone on to develop cancer before the age of thirty; the other half had remained healthy. Because blood had been drawn years before diagnosis, the samples offered something pediatric cancer research almost never has: a look backward in time.

The result was dramatic. Children who later developed cancer — on average six years after their blood had been sampled — were about eight times more likely than their healthy peers to carry antibodies against at least one core antigen involved in DNA repair. Although the cohort was small, Myklebost noted that it was the best the team could find internationally for this purpose. Even with that limitation, the association was strong enough to suggest that aberrant antibodies to the repair machinery are not merely a consequence of cancer, but a potential early footprint of the disease process itself.

The authors hypothesized that the targeting of DNA repair proteins by these auto-antibodies produces a cellular state resembling what is seen when hereditary variants disable related repair proteins and predispose carriers to cancer. In laboratory follow-up experiments, the researchers showed that the auto-antibodies can physically enter cells, particularly during the phase in which cells exit growth and prepare to divide. Once inside, the antibodies appear to home in on the TIGER organelle, a compartment where transcription factors and other short-lived but essential proteins are produced and modified. There, the antibodies could bind to and immobilize or inhibit their targets directly, hindering normal DNA repair. Such weakened repair, the authors concluded, provides a plausible mechanism for increased cellular damage that could lead to cancer development.

What might trigger a child’s immune system to turn against such fundamental molecular machinery in the first place remains an open question. Myklebost offered several candidate explanations, framed explicitly as hypotheses: the production of these antibodies could be set off by infections, by cross-reaction with proteins from microbes, by overstimulation of the immune response, or by some imbalance in immune tolerance. Each possibility points toward a different set of future experiments, and none has yet been confirmed. But the mere existence of a measurable autoimmune signature years before diagnosis reframes pediatric cancer as, at least in part, a disease the immune system may see coming.

The team is already pushing the hypothesis toward definitive proof. Myklebost said the researchers are currently investigating the effect of patient antibodies on the repair of induced mutations in cultured cells. Ultimately, the group hopes to clone the white blood cells that secrete such auto-antibodies and test whether they cause cancer in mice — an experiment that would directly establish whether the antibodies are drivers of malignancy rather than bystanders. If the causal chain is confirmed, a simple blood test for auto-antibodies against core DNA repair antigens could become a screening tool for identifying children at elevated risk, transforming the outlook for diseases such as leukemia, neuroblastoma, osteosarcoma, and myeloma that currently give no warning before they strike. The authors declare no competing interests, except that Serguienko and Myklebost have submitted a patent application for the use of core auto-antibodies as biomarkers.

Subject of Research: Auto-antibodies targeting DNA repair proteins as a potential predictor and mechanism of pediatric cancer

Article Title: Unsuspected discovery of abnormal antibodies could explain pediatric cancer

Article References: Unsuspected discovery of abnormal antibodies could explain pediatric cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pediatric cancer, auto-antibodies, DNA repair, RAD52, MGMT, immune tolerance, Frontiers in Immunology, biomarkers, cancer screening, leukemia, sarcoma, Norway